Add to a list

Inactive Instrument

genOway SA Stock Xetra

JEH

FR0004053510

Biotechnology & Medical Research

OTC Markets Traded

End-of-day quote Xetra Other stock markets
- ^EUR	-

03-30	GenOway Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-31	GenOway Société anonyme completed the acquisition of Data Science and AI assets in OMICS platform.	CI

Analysts' recommendations: genOway SA

22/11/23	GenOway: sharp rise, broker initiates buy recommendation
22/11/23	GenOway: Euroland initiates buy coverage

More recommendations

News in other languages: genOway SA

07-15	Genoway dégage 10,9 MEUR de revenus au 1er semestre 2026
07-15	Genoway : Revenus totaux de 10,9 M EUR au 1er semestre 2026 - Accélération de la croissance visée au 2nd semestre
07-02	GenOway : 20260630 Bilan semestriel du contrat de liquidité - Juin 2026
06-19	Agenda des dividendes et des AG de la semaine : session dividendes pour la galaxie Bolloré
06-03	GenOway : 20260626 Avis de convocation

More news

Managers and Directors: genOway SA

Manager	Title	Age	Since
Christian Grenier CEO	Chief Executive Officer	-	-
Alexandre Fraichard COO	Chief Operating Officer	-	01/03/1999
Benjamin Bruneau DFI	Director of Finance/CFO	-	01/10/2015

Director	Title	Age	Since
Alexandre Fraichard BRD	Director/Board Member	-	01/03/1999
Christian Grenier CHM	Chairman	-	-
Laurent Fraisse BRD	Director/Board Member	-	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.90%	+0.21%	-0.74%	+13.87%	48B
REVOLUTION MEDICINES, INC.	+1.98%	+7.31%	+430.66%	+532.17%	41.13B
IQVIA HOLDINGS INC.	+3.44%	-2.84%	+29.17%	+8.81%	37.56B
BEONE MEDICINES AG	+1.40%	-0.89%	+7.63%	+61.93%	35.91B
CELLTRION, INC.	+2.42%	+7.27%	+14.90%	+44.79%	29.86B
ASCENDIS PHARMA A/S	-0.16%	-4.02%	-	-	16.12B
MEDPACE HOLDINGS, INC.	+2.20%	+2.94%	+35.92%	+127.15%	16.05B
EUROFINS SCIENTIFIC SE	+1.25%	+1.69%	+4.72%	+18.26%	13.76B
ICON PUBLIC LIMITED COMPANY	+4.25%	-9.28%	-0.78%	-35.46%	12.1B
Average	+1.90%	-2.15%	+65.18%	+96.44%	27.83B
Weighted average by Cap.	+1.80%	-1.29%	+85.86%	+120.78%

See all sector performances

genOway est une société de biotechnologie spécialisée dans la conception et le développement de modèles de recherche moléculaires, cellulaires et animaux à forte valeur ajoutée pour les industries biopharmaceutique, chimique, agrochimique et agroalimentaire ainsi que pour la recherche académique. genOway est une société leader sur son marché. Elle appuie son développement sur la combinaison d'une large et exclusive plateforme technologique et d'une propriété intellectuelle forte combinant brevets et licences d'exploitation. genOway a conclu de nombreux contrats commerciaux avec les leaders de l'industrie pharmaceutique (BMS, Janssen, Novartis, Pfizer, etc.), et avec les centres de recherche académiques les plus prestigieux (King's College et Université de Manchester en Angleterre, Harvard, Caltech et le National Institute of Health aux Etats-Unis, l'Institut Pasteur en France, le NGFN et l'Institut Max Planck en Allemagne, etc.).

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	22.77M 26.29M 21.23M 19.53M 36.86M 2.5B 37.27M 249M 97.91M 1.25B 98.76M 96.58M 4.14B	P/E 2024 *	-	P/E 2025	-
Enterprise Value	29.49M 34.05M 27.49M 25.29M 47.73M 3.24B 48.27M 323M 127M 1.62B 128M 125M 5.37B	EV / Sales 2024	1.28x	EV / Sales 2025	1.11x
Free-Float	59.02%	Yield 2024 *	-	Yield 2025	-

03-30	GenOway Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-31	GenOway Société anonyme completed the acquisition of Data Science and AI assets in OMICS platform.	CI
12-16	GenOway Société anonyme agreed to acquire Data Science and AI assets in OMICS platform for ?7 million.	CI
11-19	GenOway Soars 18% on Strong Momentum from Chinese Joint Venture
24/09/25	GenOway Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2025	CI
27/03/25	GenOway Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2024	CI
23/09/24	GenOway Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2024	CI
19/07/24	GenOway: 15% growth in first-half sales
22/11/23	GenOway: sharp rise, broker initiates buy recommendation
22/11/23	GenOway: Euroland initiates buy coverage
17/10/23	GenOway: creation of a joint venture in Shanghai
22/09/23	GenOway: profitability target achieved ahead of schedule
21/09/23	GenOway Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	CI

03-16	GenOway : 20250627 Avis de convocation	PU
11-18	Accélération du développement en Chine : la coentreprise genOway Shanghai devient un moteur clé de croissance pour le Groupe	PU
22/09/25	GenOway : Solides résultats semestriels 2025 avec une marge d’EBITDA à 16,9%	PU
27/03/24	GenOway : Résultats annuels 2023	PU
22/09/23	GenOway : Résultats du 1er semestre 2023	PU

	2024	2025
Net sales	27.53M 31.79M 25.66M 23.6M 44.56M 3.02B 45.06M 302M 118M 1.51B 119M 117M 5.01B	28.6M 33.02M 26.66M 24.52M 46.29M 3.14B 46.81M 313M 123M 1.57B 124M 121M 5.2B
Net income	1.83M 2.11M 1.71M 1.57M 2.96M 201M 3M 20.05M 7.87M 101M 7.94M 7.76M 333M	928K 1.07M 865K 795K 1.5M 102M 1.52M 10.16M 3.99M 50.96M 4.02M 3.93M 169M
Net Debt	623K 719K 581K 534K 1.01M 68.39M 1.02M 6.82M 2.68M 34.22M 2.7M 2.64M 113M	6.72M 7.76M 6.26M 5.76M 10.87M 738M 11M 73.59M 28.88M 369M 29.13M 28.49M 1.22B

genOway SA Stock Xetra

Stocks

JEH

FR0004053510

Biotechnology & Medical Research

Valuation: genOway SA

Latest news : genOway SA

Analysts' recommendations: genOway SA

Press Releases: genOway SA

News in other languages: genOway SA

Managers and Directors: genOway SA

Other Biotechnology & Medical Research

Financials

Company Profile